Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau

被引:0
|
作者
Farias, G
GonzalezBillault, C
Maccioni, RB
机构
[1] INT CTR CANC & DEV BIOL ICC,SANTIAGO 7,CHILE
[2] UNIV CHILE,FAC SCI,DEPT BIOL,CELLULAR & MOL BIOL LAB,SANTIAGO 7,CHILE
关键词
tau isoforms; protein carbamoylation; tau glycation; paired-helical filaments; site-directed monoclonal antibodies; Alzheimer's disease;
D O I
10.1023/A:1006838626730
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The microtubule-associated protein tau is the main structural component of paired helical filaments (PHFs), which in turn are one of the major aberrant polymers found in Alzheimer's disease. Immunological studies were carried out using site-directed monoclonal and polyclonal antibodies that recognize tubulin binding epitopes on tau, to further understand the mechanisms of tau self-association into PHFs. Tau protein was subjected to either carbamoylation with potassium cyanate (KCNO) or glycation with glucose, and the immunoreactivity of the chemically-modified protein with these antibodies was compared with tau derived from paired helical filaments and with normal brain tau. The data on the immunoblot patterns of tau isoforms and the ELISA titration curves revealed significant differences between the modified tau and normal controls. However, the Western blot patterns of immunoreactive tau from the chemically-modified protein and from Alzheimer brains were similar. The data on the differences in the electrophoretic profiles and Western blots of normal brain tau as compared with solubilized paired helical filaments, insoluble tangles and tau proteins of the Alzheimer's type, provide new clues to understand the anomalous interactions of tau in Alzheimer's disease.
引用
收藏
页码:59 / 66
页数:8
相关论文
共 50 条
  • [41] Analysis of tau RNA transcripts and tau isoforms in Alzheimer's disease tissues
    Boutajangout, A
    Boom, A
    Brion, JP
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S502 - S502
  • [42] The CSF Aβ42, Tau and phosphorylated Tau as a predictive biomarker of Alzheimer's disease
    Herukka, SK
    Helisalmi, S
    Tervo, S
    Hallikainen, M
    Vanhanen, M
    Kejonen, K
    Soininen, H
    Pirttilä, T
    NEUROBIOLOGY OF AGING, 2004, 25 : S359 - S359
  • [43] FUNCTIONAL DOMAINS ON CHEMICALLY-MODIFIED TAU-PROTEIN
    FARIAS, GA
    VIAL, C
    MACCIONI, RB
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 1993, 13 (02) : 173 - 182
  • [44] Tau as a Therapeutic Target for Alzheimer's Disease
    Boutajangout, A.
    Sigurdsson, E. M.
    Krishnamurthy, P. K.
    CURRENT ALZHEIMER RESEARCH, 2011, 8 (06) : 666 - 677
  • [45] Tau polymorphisms are not associated with Alzheimer's disease
    Kwon, JM
    Nowotny, P
    Shah, PK
    Chakraverty, S
    Norton, J
    Morris, JC
    Goate, AM
    NEUROSCIENCE LETTERS, 2000, 284 (1-2) : 77 - 80
  • [46] Tau PET Imaging in Alzheimer's Disease
    Okamura, Nobuyuki
    Harada, Ryuichi
    Furumoto, Shozo
    Arai, Hiroyuki
    Yanai, Kazuhiko
    Kudo, Yukitsuka
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2014, 14 (11)
  • [47] In vivo tau imaging in Alzheimer's disease
    Villemagne, Victor
    Furumoto, Shozo
    Fodero-Tavoletti, Michelle
    Mulligan, Rachel
    Hodges, John
    Kudo, Yukitsuka
    Masters, Colin
    Yanai, Kazuhiko
    Rowe, Christopher
    Okamura, Nobuyuki
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [48] Plasma tau levels in Alzheimer's disease
    Zetterberg, Henrik
    Wilson, David
    Andreasson, Ulf
    Minthon, Lennart
    Blennow, Kaj
    Randall, Jeffrey
    Hansson, Oskar
    ALZHEIMERS RESEARCH & THERAPY, 2013, 5 (02):
  • [49] Targeting Tau Protein in Alzheimer’s Disease
    Cheng-Xin Gong
    Inge Grundke-Iqbal
    Khalid Iqbal
    Drugs & Aging, 2010, 27 : 351 - 365
  • [50] In vivo tau staging in Alzheimer's disease
    Therriault, Joseph
    Gauthier, Serge
    Rosa-Neto, Pedro
    AGING-US, 2022, 14 (17): : 6842 - 6843